Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Periodontal Therapeutics Market

Periodontal Therapeutics Market Trends

Report ID: GMI9920
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Periodontal Therapeutics Market Trends

The shift towards localized antibiotic therapies, such as minocycline hydrochloride and doxycycline hyclate, which offer targeted treatment with reduced systemic side effects, is a significant trend expected to boost the market growth.
Another notable trend is the increasing use of non-antibiotic antimicrobials like chlorhexidine gluconate, known for its effectiveness in plaque control and gingival inflammation reduction.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Global periodontal therapeutics industry was valued at USD 849.2 billion in 2023 and is anticipated to register 7.7% CAGR between 2024 and 2032, driven by growing prevalence of periodontal diseases and increasing awareness about oral health.

The retail pharmacies segment in the market recorded USD 351.1 million in 2023 owing to the increasing prevalence of periodontal diseases, such as gingivitis and periodontitis, driven by aging populations, poor oral hygiene, and lifestyle factors.

North America periodontal therapeutics market is forecasted to reach USD 756.7 million by 2032, propelled by rapidly aging population, technological advancements, heightened public awareness, and the rising prevalence of chronic diseases.

Align Technology, Inc., Bausch Health Companies Inc., Cadila Healthcare Ltd., Colgate-Palmolive Company, Danaher Corporation, Den-Mat Holdings LLC, Dentsply Sirona, Dexcel Pharma Technologies Ltd., and GlaxoSmithKline plc, among others.